Selection of SARS-CoV-2 main protease inhibitor using structure-based virtual screening

12Citations
Citations of this article
19Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Background: Conserved domains within SARS-CoV-2 nonstructural proteins represent key targets for the design of novel inhibitors. Methods: The authors aimed to identify potential SARS-CoV-2 NSP5 inhibitors using the ZINC database along with structure-based virtual screening and molecular dynamics simulation. Results: Of 13,840 compounds, 353 with robust docking scores were initially chosen, of which ten hit compounds were selected as candidates for detailed analyses. Three compounds were selected as coronavirus NSP5 inhibitors after passing absorption, distribution, metabolism, excretion and toxicity study; root and mean square deviation; and radius of gyration calculations. Conclusion: ZINC000049899562, ZINC000169336666 and ZINC000095542577 are potential NSP5 protease inhibitors that warrant further experimental studies.

Cite

CITATION STYLE

APA

Hakami, A. R., Bakheit, A. H., Almehizia, A. A., & Ghazwani, M. Y. (2022). Selection of SARS-CoV-2 main protease inhibitor using structure-based virtual screening. Future Medicinal Chemistry, 14(2), 61–79. https://doi.org/10.4155/fmc-2020-0380

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free